期刊文献+

癌胚抗原、血清前列腺特异性抗原、糖类抗原199在前列腺癌早期诊断中的应用价值

Application Value of Carcinoembryonic Antigen,Serum Prostate Specific Antigen and Carbohydrate Antigen 199 in the Early Diagnosis of Prostate Cancer
下载PDF
导出
摘要 目的探讨癌胚抗原(CEA)、血清前列腺特异性抗原(PSA)、糖类抗原199(CA199)在前列腺癌早期诊断中的应用价值。方法选取2021年4月至2023年4月我院收治的98例早期前列腺癌患者作为观察组,同期收治的98例前列腺良性疾病患者作为对照组。采用酶联免疫吸附法检测两组患者的CEA、PSA、CA199水平,分析CEA、PSA、CA199水平对早期前列腺癌的诊断价值。结果观察组的CEA、CA199、PSA水平高于对照组(P<0.05)。CEA、PSA、CA199联合检测诊断早期前列腺癌患者敏感度显著高于PSA单独检测,特异性显著高于CEA、CA199、PSA单独检测(P<0.05)。结论CEA、PSA、CA199联合检测诊断早期前列腺癌具有重要的临床意义,可为临床病情诊断及预后评估提供参考。 Objective To explore the application value of carcinoembryonic antigen(CEA),serum prostate specific antigen(PSA)and carbohydrate antigen 199(CA199)in the early diagnosis of prostate cancer.Methods 98 patients with early prostate cancer admitted to our hospital from April 2021 to April 2023 were selected as observation group,and 98 patients with benign prostate disease during the same period were selected as control group.The CEA,PSA and CA199 levels of both groups were detected by enzyme-linked immunosorbent assay to analyze the diagnostic value of CEA,PSA and CA199 levels for early prostate cancer.Results The CEA,CA199 and PSA levels of the observation group were higher than those of the control group(P<0.05).The sensitivity of combined detection of CEA,PSA,and CA199 in the diagnosis of early prostate cancer was significantly higher than that of PSA alone,and the specificity was significantly higher than that of CEA,CA199 and PSA alone(P<0.05).Conclusions The combined detection of CEA,PSA,and CA199 in the diagnosis of early prostate cancer has important clinical significance,and can provide reference for clinical diagnosis and prognosis assessment.
作者 尚璐 张慧 裴露 SHANG Lu;ZHANG Hui;PEI Lu(Clnical Laboratory,Zhengzhou Hospital of Traditional Chinese Medicine,Zhengzhou 450007,China)
出处 《临床医学工程》 2024年第5期589-590,共2页 Clinical Medicine & Engineering
关键词 癌胚抗原 血清前列腺特异性抗原 糖类抗原199 前列腺癌 Carcinoembryonic antigen Serum prostate specific antigen Carbohydrate antigen 199 Prostatic cancer
  • 相关文献

参考文献9

二级参考文献100

  • 1SiegelRL, MillerKD, JemalA. Cancer statistics, 2016[J]. CA Cancer J Clin, 2016, 66(1): 7-30.
  • 2ChenW, ZhengR, BaadePD, et al. Cancer statistics in China, 2015[J]. CA Cancer J Clin, 2016, 66(2):115-132.
  • 3ChopraS, RashidP. Management of castration-resistant (advanced) prostate cancer (CRPC): rationale, progress and future directions[J].Aust Fam Physician, 2015, 44(5): 302-305.
  • 4MolinaA, BelldegrunA. Novel therapeutic strategies for castration resistant prostate cancer: inhibition of persistent androgen production and androgen receptor mediated signaling[J]. J Urol, 2011, 185(3):787-794.
  • 5ScherHI, FizaziK, SaadF, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy[J]. N Engl J Med, 2012, 367(13):1187-1197.
  • 6PientaKJ. Preclinical mechanisms of action of docetaxel and docetaxel combinations in prostate cancer[J]. Semin Oncol, 2001, 28(4Suppl 15):3-7.
  • 7PallerCJ, AntonarakisES. Cabazitaxel: a novel second-line treatment for metastatic castration-resistant prostate cancer[J]. Drug Des Devel Ther, 2011, 5:117-124.
  • 8BertholdDR, PondGR, SobanF, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study[J]. J Clin Oncol, 2008, 26(2):242-245.
  • 9OudardS, BanuE, BeuzebocP, et al. Multicenter randomized phase II study of two schedules of docetaxel, estramustine, and prednisone versus mitoxantrone plus prednisone in patients with metastatic hormone-refractory prostate cancer[J]. J Clin Oncol, 2005, 23(15):3343-3351.
  • 10KantoffPW, HiganoCS, ShoreND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer[J]. N Engl J Med, 2010, 363(5):411-422.

共引文献110

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部